

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Henlius Biotech, Inc.

上海復宏漢霖生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2696)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

Reference is made to the announcement dated 31 March 2023 (the “**Announcement**”) and the circular dated 25 April 2023 (the “**Circular**”) of Shanghai Henlius Biotech, Inc. (the “**Company**”) in relation to, among other things, the proposed amendments to the articles of association of the Company. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

The Company would like to supplement as follows:

The Board proposes that the Articles of Association be amended to include the following Article, and to incorporate the following Article into Appendix II of the Circular:

Before Proposed Amendments to the Articles of Association	After Proposed Amendments to the Articles of Association
Article 18	Article 18

Before Proposed Amendments to the Articles of Association	After Proposed Amendments to the Articles of Association
<p>The shares issued by the Company which are not listed in domestic and overseas stock exchanges are referred to as “unlisted shares”. Upon approval by the securities regulatory authorities under the State Council, the shareholders held the unlisted shares of the Company may list and trade the shares held by them on overseas stock exchange(s). The shares transferred or converted shall comply with the regulatory procedures, provisions and requirements of the overseas securities market when listed and traded in an overseas stock exchange. The listing and trading of the aforesaid shares in an overseas stock exchange are not subject to the holding of a shareholders class meeting for voting.</p> <p>Ordinary shareholders of domestic shares and foreign shares of the Company shall have the same rights in any distribution made by dividends or other forms.</p>	<p>The shares issued by the Company which are not listed in domestic and overseas stock exchanges are referred to as “unlisted shares”. Upon filing with the securities regulatory authorities under the State Council, the shareholders held the unlisted shares of the Company may list and trade the shares held by them on overseas stock exchange(s). The shares transferred or converted shall comply with the regulatory procedures, provisions and requirements of the overseas securities market when listed and traded in an overseas stock exchange. The listing and trading of the aforesaid shares in an overseas stock exchange, <u>or the conversion of unlisted shares into foreign shares and the listing and trading of such foreign shares in an overseas stock exchange, are not subject to the holding of a shareholders meeting or a shareholders class meeting for voting.</u></p> <p><u>Overseas-listed foreign shares which are converted from unlisted shares shall be deemed as the same class of shares as other overseas-listed foreign shares.</u></p> <p>Ordinary shareholders of domestic shares and foreign shares of the Company shall have the same rights in any distribution made by dividends or other forms.</p>

The proposed amendments to the Articles of Association as stated in Appendix II of the Circular (the “**Proposed Amendments**”) together with the additional proposed amendments to the Articles of Association as set out above (the “**Additional Proposed Amendments**”) are subject to the approval of Shareholders by way of a special resolution at the AGM, and will take effect when the new Articles of Association, which will incorporate all of the Proposed Amendments and the Additional Proposed Amendments, are adopted at the AGM.

Save as disclosed above, the Board confirms that all information in the Announcement, the Circular and the Notice of AGM remain unchanged. This announcement is supplemental to and should be read in conjunction with the Announcement, the Circular and the Notice of AGM, and in that connection, the existing English and Chinese versions of the Announcement, the Circular and the Notice of AGM in the form as they are now will continue to be valid.

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Wenjie Zhang
Chairman

Hong Kong, 10 May 2023

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Wenjie Zhang as the chairman and executive director, Mr. Qiyu Chen, Mr. Yifang Wu, Ms. Xiaohui Guan, Mr. Deyong Wen and Mr. Zihou Yan as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Dr. Ruilin Song as the independent non-executive Directors.